This paper is part of a special collection highlighting the work of emerging leaders in the endocrine cancer field.
Neuroendocrine neoplasms (NENs) are challenging rare neoplasms not only for diagnosis but also for management. Immunotherapy has become a promising approach for NENs and clinical trials in phase I–II have been undertaken to evaluate the safety and efficacy of this treatment strategy. In fact, the NEN microenvironment is characterized by immunosuppressive cell composition and both tumor-associated neutrophils and macrophages are present. According to recent studies, chemokines with the CXC motif and their receptors participate in NEN progression and generate signals, which favor their immune escape. In this review, we comprehensively summarized the direct and indirect action of CXC chemokines and their receptors on NEN progression and specific immune cells’ action. In addition, we highlighted the potential value of chemokines with the CXC motif and their receptors in tracking the progression of NENs and therapy of patients with NENs.
Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 37 | 37 | 25 |
| PDF Downloads | 43 | 43 | 31 |
Online ISSN: 1479-6821
Print ISSN: 1351-0088
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
